Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 12 of the 51 sources its claims cite were checked for support.
Abstract
C3 deficiency protects against hippocampal neurodegeneration and cognitive decline in aged APP/PS1 mice despite abundant Aβ plaques.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 23 Not checked · 77 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with our previous results (5), C3 KO mice had significantly more synaptic puncta than WT mice.”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Results > Partial protection against age-related hippocampal synaptic degeneration in APP/PS1;C3 KO mice
What the sources say
- Partly supportedcites [5] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029– 13042 (2015). 26400934 PMC6605437 sourceExperimental — accuracy not yet measured
Our copy does report significantly higher synaptic puncta density in C3 KO vs WT mice, but only with age and region bounds the citing sentence drops: at P30 there were no genotype differences, at 4 months only presynaptic Vglut2-IR puncta differed (p = 0.0347) with no difference in Homer1 or colocalization, and the full increase (Vglut2 p = 0.002, Homer1 p < 0.0001, colocalization p = 0.0109) appears at 16 months in HC CA3-SR, with similar effects in DG-SM and V1 but explicitly no differences in CA1 (Results, 'Complement-deficient mice do not display age-related synapse loss'; Fig. 2 legend, 'C3 deficiency in neurodegeneration'). The unqualified statement 'C3 KO mice had significantly more synaptic puncta than WT mice' therefore overstates the source by omitting the aged-timepoint and region-specific qualifiers. The supporting evidence for the direction of the effect (and corroborating Golgi spine-density and Western blot synaptic-marker increases at 16 months) is present in the same sections. (LLM, conf=0.70)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Complement activation is elevated in human AD brain, especially in the presence of fibrillar amyloid plaques containing clusters of reactive microglia (8, 9, 11, 12)”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Discussion
What the sources say
- Supportedcites [8] Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA, Temporal accrual of complement proteins in amyloid plaques in Down’s syndrome with Alzheimer’s disease. Am J Pathol 156, 489– 499 (2000). 10666378 PMC1850044 source
The paper states that classical complement activation has been observed in AD brain and that compacted amyloid plaques in AD are often associated with activated microglia and complement proteins. Its Discussion further links abundant complement proteins in compacted plaques with activated microglia in AD-type lesions. The indexed passages provide section labels but no page numbers. (LLM, conf=0.86)
- Not checked yetcites [9] Eikelenboom P, Hack CE, Kamphorst W, Rozemuller JM, Distribution pattern and functional state of complement proteins and alpha 1-antichymotrypsin in cerebral beta/A4 deposits in Alzheimer’s disease. Res Immunol 143, 617– 620 (1992). 1455052 source
- Not checked yetcites [11] Veerhuis R, Histological and direct evidence for the role of complement in the neuroinflammation of AD. Curr Alzheimer Res 8, 34– 58 (2011). 21143154 source
- Not checked yetcites [12] Tenner AJ, Complement in Alzheimer’s disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging 22, 849– 861 (2001). 11754992 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We recently demonstrated that C3-deficiency spared age-dependent synaptic and neuronal loss in a region-specific manner, and protected against cognitive impairment in normal aging of C57BL/6 mice (5).”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Introduction
What the sources say
- Supportedcites [5] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029– 13042 (2015). 26400934 PMC6605437 source
The section 'Complement-deficient mice do not display age-related HC neuron loss' (p. ~ Results) states that age-dependent, region-specific synapse and neuron loss seen in WT C57BL/6J mice (CA3-SR, DG-SM reduced; CA1 spared) was rescued in aged male C3 KO mice, who had more synaptic puncta, higher SYP density and synaptic protein levels, higher LTP and more CA3 neurons. The section 'Complement C3-deficient mice do not display age-dependent behavioral deficits' states that C3 deficiency significantly protected mice against age-related cognitive decline, and the Summary ('C3 deficiency in neurodegeneration') reiterates that these age-related effects were spared in C3 KO mice. All elements of the citing sentence — C3-deficiency, sparing of age-dependent synaptic and neuronal loss in a region-specific manner, protection against cognitive impairment, and normal aging of C57BL/6 mice — are carried by our copy. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Previously, we reported an age-dependent loss of CA3 neurons in 16 month-old C57BL/6 mice (5).”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Discussion
What the sources say
- Supportedcites [5] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029– 13042 (2015). 26400934 PMC6605437 source
The Results section, “Complement-deficient mice do not display age-related HC neuron loss,” reports significantly fewer CA3 neurons in 16-month-old wild-type mice than at P30. The paper identifies the wild-type mice as C57BL/6J. The 16-month versus 4-month comparison was not significant, so the demonstrated loss is relative to P30. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“16-month-old APP/PS1;C3 KO mice performed significantly better on a learning and memory task than APP/PS1 mice, despite having more cerebral Aβ plaques.”
- Also stated in: § Sparing of cognitive decline in plaque-burdened aged APP/PS1;C3 KO mice · plain
“Reversal learning in APP/PS1;C3 KO mice was similar to that of WT mice and C3 KO mice, and was significantly better than that of APP/PS1 mice on Days 4 and 5”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Sparing of cognitive decline in plaque-burdened aged APP/PS1;C3 KO mice · plain
48 more claims
Create a free account to see all 111 claims and to verify the 39 references still open.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 35
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Actually, inflammation even happens earlier than protein aggregation.”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“increasing evidence demonstrate that immune signaling may not just be a consequence of protein aggregation in the brain, but that it actually causes the buildup of aggregates at the earliest stages of the disease process.15–17”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, IFN-γ-induced C3 expression in an amyloidogenic mouse model reduced plaque load but resulted in increased loss of synapses and cognitive dysfunction [152, 284].”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [284]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings align with previous reports suggesting that plaque morphology, rather than total amyloid burden, may be a key factor in neurotoxicity and disease progression and suggest that this could be an important role for plaque‐associated PLCγ2 expressing microglia (Casali et al. 2020; Shi et al. 2017; Yuan et al. 2016).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Shi et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, recent data indicate that microglia and astrocytes coordinate their functions in many ways, both in the healthy and diseased brain [14–21].”
From Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates (2021) · cites this paper as [17]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Discussion
“Recently, Hong et al. reported similar Aβ oligomer-induced, complement-mediated and microglia-dependent synaptic loss in young, pre-plaque AD mice that was rescued by the genetic deletion of C1q or C3, or by treatment with a C1qa blocking antibody (8).”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > References
“10. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B, Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712– 716 (2016). 27033548 PMC5094372”
Citations
Cites
1 retracted
Bialas, A. R., & Stevens, B. (2013) · Nature Neuroscience · doi:10.1038/nn.3560 · Cited by 519
Self-citationRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“Synapse loss is an early and important change in AD brain (41), and hippocampal synapse loss is observed in APP/PS1 mice (28, 29).”
BackgroundTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Self-citationComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343
Self-citationThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Self-citationMicroglia promote learning-dependent synapse formation through brain-derived neurotrophic factor
Parkhurst, C. N., Yang, G., Ninan, I., Savas, J. N., Yates, J. R., Lafaille, J. J., Hempstead, B. L., Littman, D. R., & Gan, W.-B. (2013) · Cell · doi:10.1016/j.cell.2013.11.030 · Cited by 2,599 · cited 1×
“Furthermore, mice deficient in BDNF in microglia have deficits in learning andhippocampal synapse formation, indicating thatmicroglial BDNF signaling plays an important role in hippocampal function (60).”
BackgroundSynapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Unbiased stereological estimation of the number of neurons in the human hippocampus
West, M. J., & Gundersen, H. J. G. (1990) · Journal of Comparative Neurology · doi:10.1002/cne.902960102 · Cited by 1,153 · cited 2×
“M. J. West, H. J. G. Gundersen, Unbiased stereological estimation of the number of neurons in the human hippocampus.”
MethodMicroglial priming in neurodegenerative disease
Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127 · cited 1×
“Others have suggested that C3-dependent microglia overactivation is responsible for neuroinflammation, which accelerates pathogenesis in neurodegenerative diseases (55).”
BackgroundJin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 1×
“Preparation of synaptosome fractions Synaptosome fractions were prepared as described previously (66).”
MethodKoffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850
Complement activation by beta-amyloid in Alzheimer disease.
Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., & Ward, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10016 · Cited by 817
Lian, H., Yang, L., Cole, A., Sun, L., Chiang, A. C.-A., Fowler, S. W., Shim, D. J., Rodriguez-Rivera, J., Taglialatela, G., Jankowsky, J. L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.11.018 · Cited by 697
Spangenberg, E. E., Lee, R. J., Najafi, A. R., Rice, R. A., Elmore, M. R. P., Blurton-Jones, M., West, B. L., & Green, K. N. (2016) · Brain · doi:10.1093/brain/aww016 · Cited by 695
Lian, H., Litvinchuk, A., Chiang, A. C.-A., Aithmitti, N., Jankowsky, J. L., & Zheng, H. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2117-15.2016 · Cited by 597
Olmos-Alonso, A., Schetters, S. T. T., Sri, S., Askew, K., Mancuso, R., Vargas-Caballero, M., Holscher, C., Perry, V. H., & Gomez-Nicola, D. (2016) · Brain · doi:10.1093/brain/awv379 · Cited by 532
Morrison, H. W., & Filosa, J. A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-4 · Cited by 506
Wessels, M. R., Butko, P., Ma, M., Warren, H. B., Lage, A. L., & Carroll, M. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11490 · Cited by 503 · cited 1×
“129S4-C3tm1Crr/J) (63) were obtained from The Jackson Laboratory.”
MethodProminent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446 · cited 4×
“Both C3 deficiency and inhibition of C3 convertase by overexpression of sCrry in J20 hAPP transgenicmice led to an age-dependent increase in plaqueburden (21,22).”
BackgroundInfluentialA Dramatic Increase of C1q Protein in the CNS during Normal Aging
Stephan, A. H., Madison, D. V., Mateos, J. M., Fraser, D. A., Lovelett, E. A., Coutellier, L., Kim, L., Tsai, H.-H., Huang, E. J., Rowitch, D. H., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1333-13.2013 · Cited by 423
Veerhuis, R., Nielsen, H. M., & Tenner, A. J. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.003 · Cited by 419
Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline
Shi, Q., Colodner, K. J., Matousek, S. B., Merry, K., Hong, S., Kenison, J. E., Frost, J. L., Le, K. X., Li, S., Dodart, J.-C., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1698-15.2015 · Cited by 368
Self-citationInflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models
Spangenberg, E. E., & Green, K. N. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.003 · Cited by 352 · cited 1×
“In the brain environment undergoing injury or disease, chronic activation of microglia may contribute to synaptic degeneration and memory decline (34).”
BackgroundArendash, G. W., King, D. L., Gordon, M. N., Morgan, D., Hatcher, J. M., Hope, C. E., & Diamond, D. M. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03186-3 · Cited by 349
Absence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease
Fonseca, M. I., Zhou, J., Botto, M., & Tenner, A. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0901-04.2004 · Cited by 345 · cited 4×
“C1qa-deficient transgenic 2576 hAPP mice show increased iC3b deposition in brain, reduced gliosis and neuron loss in several brain regions, and partial protection of synapses in the hippocampal CA3 region, suggesting selective regional vulnerability of synapses and differential effects of various complement pathways (…”
BackgroundResultInfluentialJordão, J. F., Thévenot, E., Markham-Coultes, K., Scarcelli, T., Weng, Y.-Q., Xhima, K., O'Reilly, M., Huang, Y., McLaurin, J., Hynynen, K., et al. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.05.008 · Cited by 326 · cited 1×
“Confocal analysis of glia morphology and association with Ab plaques Immunofluorescence for Ab plaques (6E10), microglia/macrophages (Iba-1), and astrocytes (GFAP) was detected by confocal microscopy (LSM 710, Carl Zeiss) using a methodology described previously (64).”
MethodMaier, M., Peng, Y., Jiang, L., Seabrook, T. J., Carroll, M. C., & Lemere, C. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0829-08.2008 · Cited by 323 · cited 6×
“C3 inhibition enhanced plaque deposition and promoted neurodegeneration in J20 hAPP mice either by overexpression of sCrry (22) or by genetic deletion of C3 (21).”
BackgroundMethodInfluentialSelf-citationInflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer’s disease
Matsuoka, Y., Picciano, M., Malester, B., LaFrancois, J., Zehr, C., Daeschner, J. M., Olschowka, J. A., Fonseca, M. I., O’Banion, M. K., Tenner, A. J., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64085-0 · Cited by 303 · cited 1×
“However, Iba-1 immunoreactivity and the amount of CD68 by Western blot were not significantly different between J20;C3 KO and J20 mice (15).”
BackgroundSelf-citationFonseca, M. I., Ager, R. R., Chu, S.-H., Yazan, O., Sanderson, S. D., LaFerla, F. M., Taylor, S. M., Woodruff, T. M., & Tenner, A. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901005 · Cited by 268
Quantifying Synapses: an Immunocytochemistry-based Assay to Quantify Synapse Number
Ippolito, D. M., & Eroglu, C. (2010) · Journal of Visualized Experiments · doi:10.3791/2270 · Cited by 251 · cited 1×
“Synaptic puncta staining and analysis Synaptic puncta staining and analysis were performed as previously described (5, 65).”
MethodDickey, C. A., Loring, J. F., Montgomery, J., Gordon, M. N., Eastman, P. S., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05219.2003 · Cited by 242 · cited 1×
“Synapse loss is an early and important change in AD brain (41), and hippocampal synapse loss is observed in APP/PS1 mice (28, 29).”
BackgroundNovel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes
Chung, W.-S., Verghese, P. B., Chakraborty, C., Joung, J., Hyman, B. T., Ulrich, J. D., Holtzman, D. M., & Barres, B. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609896113 · Cited by 242 · cited 1×
“Given that microglia and astrocytes, both of which express complement, are highly phagocytic and participate in synapse pruning (10, 43), our findings that C3 deficiency protected against hippocampal synaptic decline in two mouse models (C3 KO and APP/PS1;C3 KO) suggest that complement C3 or its downstream activation…”
BackgroundNeurodegeneration by Activation of the Microglial Complement-Phagosome Pathway
Bodea, L.-G., Wang, Y., Linnartz-Gerlach, B., Kopatz, J., Sinkkonen, L., Musgrove, R., Kaoma, T., Muller, A., Vallar, L., Di Monte, D. A., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5002-13.2014 · Cited by 234 · cited 1×
“For instance, lipopolysaccharide-induced loss of dopaminergic neurons was inhibited by C3 deficiency (56).”
BackgroundThe role of complement and activated microglia in the pathogenesis of Alzheimer's disease
Eikelenboom, P., & Veerhuis, R. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00108-x · Cited by 206
Stoltzner, S. E., Grenfell, T. J., Mori, C., Wisniewski, K. E., Wisniewski, T. M., Selkoe, D. J., & Lemere, C. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64753-0 · Cited by 187 · cited 6×
“This possibility would be consistent with our previous findings that genetic deletion or antibody blocking of C1qa protected hippocampal synapses from Ab oligomer–induced damage (8).”
BackgroundResultInfluentialSelf-citationFu, H., Liu, B., Frost, J. L., Hong, S., Jin, M., Ostaszewski, B., Shankar, G. M., Costantino, I. M., Carroll, M. C., Mayadas, T. N., et al. (2012) · Glia · doi:10.1002/glia.22331 · Cited by 180
Self-citationWilliams, P. A., Tribble, J. R., Pepper, K. W., Cross, S. D., Morgan, B. P., Morgan, J. E., John, S. W. M., & Howell, G. R. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0091-6 · Cited by 180 · cited 1×
“Similarly, the loss of retinal ganglion cell synapses and dendrites (which precede axon and soma loss) in a genetic mouse model (DBA/2J) and an inducible rat model (microbead) of glaucomawere rescued by genetic deletion ofC1qa in the mouse model and C1 inhibition in the rat model (38).”
BackgroundBeglopoulos, V., Sun, X., Saura, C. A., Lemere, C. A., Kim, R. D., & Shen, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409544200 · Cited by 154
Self-citationC3-dependent mechanism of microglial priming relevant to multiple sclerosis
Ramaglia, V., Hughes, T. R., Donev, R. M., Ruseva, M. M., Wu, X., Huitinga, I., Baas, F., Neal, J. W., & Morgan, B. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111924109 · Cited by 151 · cited 1×
“In experimental autoimmune encephalomyelitis, a mouse model of human multiple sclerosis, C3 overactivation in Crry-deficient mice increased microglial overactivation and exacerbated neurodegeneration (57).”
BackgroundHaga, S., Ikeda, K., Sato, M., & Ishii, T. (1993) · Brain Research · doi:10.1016/0006-8993(93)91698-r · Cited by 145 · cited 1×
“Ab peptides up-regulate C3 production by microglia and astrocytes in vitro (13, 14) and also increase C3 expression and deposition in AD mouse brain in vivo (10, 15–18).”
BackgroundMicroglial activation in early stages of amyloid β protein deposition
Sasaki, A., Yamaguchi, H., Ogawa, A., Sugihara, S., & Nakazato, Y. (1997) · Acta Neuropathologica · doi:10.1007/s004010050713 · Cited by 132
Widespread Changes in Dendritic Spines in a Model of Alzheimer's Disease
Knafo, S., Alonso-Nanclares, L., Gonzalez-Soriano, J., Merino-Serrais, P., Fernaud-Espinosa, I., Ferrer, I., & DeFelipe, J. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn111 · Cited by 132 · cited 1×
“Although both plaque-associated and plaque-independent hippocampal synaptic degeneration have been observed in aged APP/PS1 mice (42), we found reduced synaptic degeneration despite increased plaque load in aged APP/PS1;C3 KO mice compared to APP/PS1 mice, indicating that the presence of plaques alone did not induce n…”
BackgroundComplement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer’s disease
Zhou, J., Fonseca, M. I., Pisalyaput, K., & Tenner, A. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05558.x · Cited by 130 · cited 1×
“Complement activation is elevated in human AD brain, especially in the presence of fibrillar amyloid plaques containing clusters of reactivemicroglia (8, 9, 11, 12) and in the brains of AD amyloidosis mouse models (10, 17, 31).”
BackgroundFilali, M., & Lalonde, R. (2009) · Brain Research · doi:10.1016/j.brainres.2009.07.066 · Cited by 121 · cited 1×
“Progressive cognitive impairment in water maze tests is observed in aged APPswe/PS1dE9 mice (an AD-like mouse model of amyloidosis) and is correlated with progressive Ab deposition, neuroinflammation, and degeneration of synapses and neurons (25, 32).”
BackgroundReichwald, J., Danner, S., Wiederhold, K.-H., & Staufenbiel, M. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-35 · Cited by 121
Silverman, S. M., Kim, B.-J., Howell, G. R., Miller, J., John, S. W. M., Wordinger, R. J., & Clark, A. F. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0089-0 · Cited by 91
Webster, S., Glabe, C., & Rogers, J. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2852 · Cited by 84 · cited 1×
“Complement has been shown to promote the nucleation phase of Ab aggregation (54), suggesting that, once activated, complementmay perpetuate ADpathogenesis.”
BackgroundComplement in Alzheimer's disease: opportunities for modulating protective and pathogenic events
Tenner, A. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00301-3 · Cited by 81 · cited 2×
“Complement activation is elevated in human AD brain, especially in the presence of fibrillar amyloid plaques containing clusters of reactivemicroglia (8, 9, 11, 12) and in the brains of AD amyloidosis mouse models (10, 17, 31).”
BackgroundHistological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Veerhuis, R. (2011) · Current Alzheimer Research · doi:10.2174/156720511794604589 · Cited by 80 · cited 2×
“Complement activation is elevated in human AD brain, especially in the presence of fibrillar amyloid plaques containing clusters of reactivemicroglia (8, 9, 11, 12) and in the brains of AD amyloidosis mouse models (10, 17, 31).”
BackgroundAltered cognitive performance and synaptic function in the hippocampus of mice lacking C3
Perez-Alcazar, M., Daborg, J., Stokowska, A., Wasling, P., Björefeldt, A., Kalm, M., Zetterberg, H., Carlström, K. E., Blomgren, K., Ekdahl, C. T., et al. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2013.12.013 · Cited by 76
Amyloid precursor protein increases cortical neuron size in transgenic mice
Oh, E. S., Savonenko, A. V., King, J. F., Fangmark Tucker, S. M., Rudow, G. L., Xu, G., Borchelt, D. R., & Troncoso, J. C. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.024 · Cited by 75 · cited 1×
“Age-dependent neuron loss in APPswe/PS1dE9 mice has been found in striatum (47) but not cortex (48) or hippocampal CA1 (30).”
BackgroundDucruet, A. F., Zacharia, B. E., Sosunov, S. A., Gigante, P. R., Yeh, M. L., Gorski, J. W., Otten, M. L., Hwang, R. Y., DeRosa, P. A., Hickman, Z. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038664 · Cited by 75 · cited 1×
“Others have reported that low-dose treatment with the same C3aR antagonist in an ischemia/ reperfusion strokemodel in C57BL/6mice resulted in enhanced neurogenesis, histologic and functional neuroprotection, and an antiinflammatory effect (for example, the absence of T lymphocytes expressing C3aRmigrating into the isc…”
BackgroundBerg, A., Zelano, J., Stephan, A. H., Thams, S., Barres, B. A., Pekny, M., Pekna, M., & Cullheim, S. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.06.008 · Cited by 63
Synaptic contact number and size in stratum radiatum CA1 of APP/PS1ΔE9 transgenic mice
West, M. J., Bach, G., Søderman, A., & Jensen, J. L. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.01.009 · Cited by 48 · cited 14×
“Quantitative image analysis revealed that Iba-1 immunoreactivity (% area) was significantly reduced by 28.8% in the hippocampal CA3 region (P < 0.05) and slightly reduced by 19.3% (nonsignificant trend) in the hippocampal CA1 region in APP/PS1;C3 KO mice; no significant differences were seen in the dentate gyrus (Fig.”
BackgroundInfluentialInduction of complement proteins in a mouse model for cerebral microvascular Aβ deposition
Fan, R., DeFilippis, K., & Van Nostrand, W. E. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-22 · Cited by 47 · cited 1×
“S6, F and G), consistent with our previous study (16).”
ResultHippocampus-dependent place learning enables spatial flexibility in C57BL6/N mice
Kleinknecht, K. R., Bedenk, B. T., Kaltwasser, S. F., Grünecker, B., Yen, Y.-C., Czisch, M., & Wotjak, C. T. (2012) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2012.00087 · Cited by 46
Synaptic Changes in the Dentate Gyrus of APP/PS1 Transgenic Mice Revealed by Electron Microscopy
Alonso-Nanclares, L., Merino-Serrais, P., Gonzalez, S., & DeFelipe, J. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31828d41ec · Cited by 45 · cited 1×
“Synapse loss is an early and important change in AD brain (41), and hippocampal synapse loss is observed in APP/PS1 mice (28, 29).”
BackgroundAging causes partial loss of basal forebrain but no loss of pontine reticular cholinergic neurons
Baskerville, K. A., Kent, C., Nicolle, M. M., Gallagher, M., & McKinney, M. (2006) · NeuroReport · doi:10.1097/wnr.0b013e32800fef5a · Cited by 44 · cited 1×
“CA3 neurons receive input from other CA3 neurons through recurrent connections as well as medial septum and the diagonal band of Broca, both of which show degenerative changes during aging (49, 50).”
BackgroundEikelenboom, P., Hack, C. E., Kamphorst, W., & Rozemuller, J. M. (1992) · Research in Immunology · doi:10.1016/0923-2494(92)80044-l · Cited by 40
Neher, M. D., Rich, M. C., Keene, C., Weckbach, S., Bolden, A. L., Losacco, J. T., Patane, J., Flierl, M. A., Kulik, L. N., Holers, V. M., et al. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-95 · Cited by 37
Choucair-Jaafar, N., Laporte, V., Levy, R., Poindron, P., Lombard, Y., & Gies, J.-P. (2011) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00811.x · Cited by 35
Complement C1q Does Not Bind Monomeric β-Amyloid
Snyder, S. W., Wang, G. T., Barrett, L., Ladror, U. S., Casuto, D., Lee, C. M., Krafft, G. A., Holzman, R. B., & Holzman, T. F. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1121 · Cited by 34 · cited 1×
“Ab-induced complement activation is strongly determined by the degree of Ab fibrillarity (51, 52).”
BackgroundWoodruff, T. M., & Tenner, A. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00220 · Cited by 26
Molecular signatures of neurodegeneration in the cortex of PS1/PS2 double knockout mice
Mirnics, K., Norstrom, E. M., Garbett, K., Choi, S., Zhang, X., Ebert, P., & Sisodia, S. S. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-14 · Cited by 23 · cited 1×
“Previous reports demonstrated up-regulation of C1q in the hippocampus and GFAP and cathepsin S in the cortex and hippocampus in conditional PS1/2 double-knockout mice and increased expression of complement cascade components C1q,C3aR, andC4b in the hippocampi of PS1/2 double-knockoutmice (61, 62).”
BackgroundRichner, M., Bach, G., & West, M. J. (2009) · Brain Research · doi:10.1016/j.brainres.2009.02.025 · Cited by 20 · cited 1×
“Age-dependent neuron loss in APPswe/PS1dE9 mice has been found in striatum (47) but not cortex (48) or hippocampal CA1 (30).”
BackgroundLi, D., Wang, J., Yew, D. T., Lucy Forster, E., & Yao, Z. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.08.006 · Cited by 12 · cited 1×
“CA3 neurons receive input from other CA3 neurons through recurrent connections as well as medial septum and the diagonal band of Broca, both of which show degenerative changes during aging (49, 50).”
Background
Cited by
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
Microglia emerge as central players in brain disease
Salter, M. W., & Stevens, B. (2017) · Nature Medicine · doi:10.1038/nm.4397 · Cited by 1,767
Self-citationRole of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Metadata
- Authors
- Shi, Q., Chowdhury, S., Ma, R., Le, K. X., Hong, S., Caldarone, B. J., Stevens, B., & Lemere, C. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Boston Children's Hospital (US)
- Corresponding author
- Lemere, Cynthia A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-05-31
- Volume
- 9
- Issue
- 392
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6936623
- OpenAlex
- W2618794795
- Semantic Scholar
- 9b3f6a14369dd65bfc394e92ccb26bd20b83ccd0
- Cited by
- 593
- References
- 70
- Citations by year
- 2026: 47 · 2025: 72 · 2024: 75 · 2023: 71 · 2022: 66 · 2021: 88 · 2020: 64 · 2019: 50 · 2018: 43 · 2017: 17
- FWCI
- 35.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (award298479, R21 AG044713)
- BrightFocus Foundation (award298478, A2016425F)
- Fidelity Biosciences (award298481, (F-PRIME), award298470, F-PRIME)
- Edward R and Anne G Lefler (award298482, Fellowship)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- complement C3, complement system, neurodegeneration, Alzheimer's disease, APP/PS1 mice, amyloid plaques, microglia, synaptic loss, neuronal loss, aging, glial response
- MeSH terms
- Aging, Animals, Astrocytes, Complement C3, Gliosis, Hippocampus, Mice, Inbred C57BL, Nerve Degeneration, Solubility, Synapses, Cytokines, Amyloid beta-Protein Precursor, Mice, Knockout, Presenilin-1, Plaque, Amyloid, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.